Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2020

01-12-2020 | Prediabetes | Research

Diagnostic accuracy of the Finnish Diabetes Risk Score for the prediction of undiagnosed type 2 diabetes, prediabetes, and metabolic syndrome in the Lebanese University

Authors: Maher Abdallah, Safa Sharbaji, Marwa Sharbaji, Zeina Daher, Tarek Faour, Zeinab Mansour, Mohammad Hneino

Published in: Diabetology & Metabolic Syndrome | Issue 1/2020

Login to get access

Abstract

Background

Risk scores were mainly proved to predict undiagnosed type 2 diabetes mellitus (UT2DM) in a non-invasive manner and to guide earlier clinical treatment. The objective of the present study was to assess the performance of the Finnish Diabetes Risk Score (FINDRISC) for detecting three outcomes: UT2DM, prediabetes, and the metabolic syndrome (MS).

Methods

This was a prospective, cross-sectional study during which employees aged between 30 and 64, with no known diabetes and working within the faculties of the Lebanese University (LU) were conveniently recruited. Participants completed the FINDRISC questionnaire and their glucose levels were examined using both fasting blood glucose (FBG) and oral glucose tolerance tests (OGTT). Furthermore, they underwent lipid profile tests with anthropometry.

Results

Of 713 subjects, 397 subjects (55.2% female; 44.8% male) completed the blood tests and thus were considered as the sample population. 7.6% had UT2DM, 22.9% prediabetes and 35.8% had MS, where men had higher prevalence than women for these 3 outcomes (P = 0.001, P = 0.003 and P = 0.001) respectively. The AUROC value with 95% Confidence Interval (CI) for detecting UT2DM was 0.795 (0.822 in men and 0.725 in women), 0.621(0.648 in men and 0.59 in women) for prediabetes and 0.710 (0.734 in men and 0.705 in women) for MS. The correspondent optimal cut-off point for UT2DM was 11.5 (sensitivity = 83.3% and specificity = 61.3%), 9.5 for prediabetes (sensitivity = 73.6% and specificity = 43.1%) and 10.5 (sensitivity = 69.7%; specificity = 56.5%) for MS.

Conclusion

The FINDRISC can be considered a simple, quick, inexpensive, and non-invasive instrument to use in a Lebanese community of working people who are unaware of their health status and who usually report being extremely busy because of their daily hectic work for the screening of UT2DM and MS. However, it poorly screens for prediabetes in this context.
Literature
1.
go back to reference Goyal R, Jialal I. Diabetes Mellitus Type 2. Treasure Island (FL): StatPearls Publishing; 2019. Goyal R, Jialal I. Diabetes Mellitus Type 2. Treasure Island (FL): StatPearls Publishing; 2019.
2.
4.
go back to reference Roberts CK, Hevener AL, Barnard RJ. metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013;3:1–58.PubMedPubMedCentral Roberts CK, Hevener AL, Barnard RJ. metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013;3:1–58.PubMedPubMedCentral
5.
go back to reference Centers for Disease Control and Prevention. National Diabetes Statistics Report. U.S. Dept of Health and Human Services; 2017 p. 20. Centers for Disease Control and Prevention. National Diabetes Statistics Report. U.S. Dept of Health and Human Services; 2017 p. 20.
7.
go back to reference International Diabetes Federation. Global Guideline for Type 2 Diabetes, Clinical guidelines task force, 2012. International Diabetes Federation. Global Guideline for Type 2 Diabetes, Clinical guidelines task force, 2012.
9.
go back to reference Nasrallah MP, Nakhoul NF, Nasreddine L, Mouneimne Y, Abiad MG, Tamim H. Prevalence of diabetes in Greater Beirut area: Worsening over time. Endocr Pract. 2017;23:1091–100.PubMedCrossRef Nasrallah MP, Nakhoul NF, Nasreddine L, Mouneimne Y, Abiad MG, Tamim H. Prevalence of diabetes in Greater Beirut area: Worsening over time. Endocr Pract. 2017;23:1091–100.PubMedCrossRef
10.
go back to reference Costanian C, Bennett K, Hwalla N, Assaad S, Sibai AM. Prevalence, correlates and management of type 2 diabetes mellitus in Lebanon: Findings from a national population-based study. Diabetes Res Clin Pract. 2014;105:408–15.PubMedCrossRef Costanian C, Bennett K, Hwalla N, Assaad S, Sibai AM. Prevalence, correlates and management of type 2 diabetes mellitus in Lebanon: Findings from a national population-based study. Diabetes Res Clin Pract. 2014;105:408–15.PubMedCrossRef
11.
go back to reference Ghassibe-Sabbagh M, Deeb M, Salloum AK, Mouzaya F, Haber M, Al-Sarraj Y, Chami Y, Akle Y, Hirbli K, Nemr R, Ahdab R, Platt DE, Abchee AB, El-Shanti H, Alloua AP. Multivariate epidemiologic analysis of type 2 diabetes mellitus risks in the Lebanese population. Diabetol Metab Syndr. 2014;1(6):89.CrossRef Ghassibe-Sabbagh M, Deeb M, Salloum AK, Mouzaya F, Haber M, Al-Sarraj Y, Chami Y, Akle Y, Hirbli K, Nemr R, Ahdab R, Platt DE, Abchee AB, El-Shanti H, Alloua AP. Multivariate epidemiologic analysis of type 2 diabetes mellitus risks in the Lebanese population. Diabetol Metab Syndr. 2014;1(6):89.CrossRef
12.
go back to reference Ansarimoghaddam A, Adineh HA, Iraj Z, Sohrab I, HosseinZadeh A, Ali H. Prevalence of metabolic syndrome in Middle-East countries: Meta-analysis of cross-sectional studies. Diabetes Metab Syndr. 2018;12(2):195–201.PubMedCrossRef Ansarimoghaddam A, Adineh HA, Iraj Z, Sohrab I, HosseinZadeh A, Ali H. Prevalence of metabolic syndrome in Middle-East countries: Meta-analysis of cross-sectional studies. Diabetes Metab Syndr. 2018;12(2):195–201.PubMedCrossRef
13.
go back to reference Zhang P, Gregg E. Global economic burden of diabetes and its implications. Lancet Diabetes Endocrinol. 2017;5:404–5.PubMedCrossRef Zhang P, Gregg E. Global economic burden of diabetes and its implications. Lancet Diabetes Endocrinol. 2017;5:404–5.PubMedCrossRef
14.
go back to reference American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018;41(Suppl 1):13–27.CrossRef American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018;41(Suppl 1):13–27.CrossRef
15.
go back to reference Buijsse B, Simmons RK, Griffin SJ, Schulze MB. Risk Assessment Tools for Identifying Individuals at Risk of Developing Type 2 Diabetes. Epidemiol Rev. 2011;33:46–62.PubMedPubMedCentralCrossRef Buijsse B, Simmons RK, Griffin SJ, Schulze MB. Risk Assessment Tools for Identifying Individuals at Risk of Developing Type 2 Diabetes. Epidemiol Rev. 2011;33:46–62.PubMedPubMedCentralCrossRef
16.
go back to reference Bang H, Edwards AM, Bomback AS, Ballantyne CM, Brillon D, Callahan MA, Teutsch SM, Mushlin AI, Kern LM. Development and validation of a patient self-assessment score for diabetes risk. Ann Intern Med. 2009;151:775–83.PubMedPubMedCentralCrossRef Bang H, Edwards AM, Bomback AS, Ballantyne CM, Brillon D, Callahan MA, Teutsch SM, Mushlin AI, Kern LM. Development and validation of a patient self-assessment score for diabetes risk. Ann Intern Med. 2009;151:775–83.PubMedPubMedCentralCrossRef
17.
go back to reference Schulze MB, Hoffmann K, Boeing H, Linseisen J, Rohrmann S, Möhlig M, Pfeiffer AFH, Spranger J, Thamer C, Häring HU, Fritsche A, Joost HG. An Accurate Risk Score Based on Anthropometric, Dietary, and Lifestyle Factors to Predict the Development of Type 2 Diabetes. Diabetes Care. 2007;30(1):510–5.PubMedCrossRef Schulze MB, Hoffmann K, Boeing H, Linseisen J, Rohrmann S, Möhlig M, Pfeiffer AFH, Spranger J, Thamer C, Häring HU, Fritsche A, Joost HG. An Accurate Risk Score Based on Anthropometric, Dietary, and Lifestyle Factors to Predict the Development of Type 2 Diabetes. Diabetes Care. 2007;30(1):510–5.PubMedCrossRef
18.
go back to reference Brown N, Critchley J, Bogowicz P, Mayige M, Unwin N. Risk scores based on self-reported or available clinical data to detect undiagnosed Type 2 Diabetes: a systematic review. Diabetes Res Clin Pract. 2012;98(3):369–85.PubMedCrossRef Brown N, Critchley J, Bogowicz P, Mayige M, Unwin N. Risk scores based on self-reported or available clinical data to detect undiagnosed Type 2 Diabetes: a systematic review. Diabetes Res Clin Pract. 2012;98(3):369–85.PubMedCrossRef
20.
go back to reference Lindstrom J, Tuomilehto J. The Diabetes Risk Score: A practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(3):725–31.PubMedCrossRef Lindstrom J, Tuomilehto J. The Diabetes Risk Score: A practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(3):725–31.PubMedCrossRef
23.
go back to reference Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, Myers MG, Ogedegbe G, Schwartz JE, Townsend RR, Urbina EM, Viera AJ, White WB, Wright JT Jr. Measurement of Blood Pressure in Humans: A Scientific Statement from the American Heart Association. Hypertension. 2019;73(5):35–66.CrossRef Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, Myers MG, Ogedegbe G, Schwartz JE, Townsend RR, Urbina EM, Viera AJ, White WB, Wright JT Jr. Measurement of Blood Pressure in Humans: A Scientific Statement from the American Heart Association. Hypertension. 2019;73(5):35–66.CrossRef
24.
go back to reference Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–50225.PubMedCrossRef Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–50225.PubMedCrossRef
26.
go back to reference Mortada D, Wehbe T, Abou JE. Prevalence of diabetes and pre-diabetes in a cohort of high risk undiagnosed patients. Int J Food Sci Nutr Diet. 2018;7(1):372–6. Mortada D, Wehbe T, Abou JE. Prevalence of diabetes and pre-diabetes in a cohort of high risk undiagnosed patients. Int J Food Sci Nutr Diet. 2018;7(1):372–6.
27.
go back to reference Ghadieh R, Mosleh J, Al Hayek S, Merhi S, El-Hayek FJ. The relationship between hypovitaminosis D and metabolic syndrome: a cross sectional study among employees of a private university in Lebanon. BMC Nutr. 2018;4:36.PubMedPubMedCentralCrossRef Ghadieh R, Mosleh J, Al Hayek S, Merhi S, El-Hayek FJ. The relationship between hypovitaminosis D and metabolic syndrome: a cross sectional study among employees of a private university in Lebanon. BMC Nutr. 2018;4:36.PubMedPubMedCentralCrossRef
28.
go back to reference Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, Horton ES, Castorino K, Tate DF. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065–79.PubMedPubMedCentralCrossRef Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, Horton ES, Castorino K, Tate DF. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065–79.PubMedPubMedCentralCrossRef
29.
go back to reference Siren R, Eriksson JG, Vanhanen H. Waist circumference a good indicator of future risk for type 2 diabetes and cardiovascular disease. BMC Public Health. 2012;12:631.PubMedPubMedCentralCrossRef Siren R, Eriksson JG, Vanhanen H. Waist circumference a good indicator of future risk for type 2 diabetes and cardiovascular disease. BMC Public Health. 2012;12:631.PubMedPubMedCentralCrossRef
30.
go back to reference Saaristo T, Peltonen M, Lindström J, Saarikoski L, Sundvall J, Eriksson JG, Tuomilehto J. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diabetes Vasc Dis Res. 2005;2(2):67–72.CrossRef Saaristo T, Peltonen M, Lindström J, Saarikoski L, Sundvall J, Eriksson JG, Tuomilehto J. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diabetes Vasc Dis Res. 2005;2(2):67–72.CrossRef
31.
go back to reference Vazquez G, Duval S, Jacobs DR, Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiol Rev. 2007;29:115–28.PubMedCrossRef Vazquez G, Duval S, Jacobs DR, Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiol Rev. 2007;29:115–28.PubMedCrossRef
32.
go back to reference Ku GMV, Kegels G. The performance of the Finnish Diabetes Risk Score, a modified Finnish Diabetes Risk Score and a simplified Finnish Diabetes Risk Score in community-based cross-sectional screening of undiagnosed type 2 diabetes in the Philippines. Prim Care Diab. 2013;7(4):249–59.CrossRef Ku GMV, Kegels G. The performance of the Finnish Diabetes Risk Score, a modified Finnish Diabetes Risk Score and a simplified Finnish Diabetes Risk Score in community-based cross-sectional screening of undiagnosed type 2 diabetes in the Philippines. Prim Care Diab. 2013;7(4):249–59.CrossRef
33.
go back to reference Al Khalaf MM, Eid MM, Najjar HA, Alhajry KM, Doi SA, Thalib L. screening for diabetes in Kuwait and evaluation of risk scores. East Mediterr Health J. 2010;16(7):725–31.PubMedCrossRef Al Khalaf MM, Eid MM, Najjar HA, Alhajry KM, Doi SA, Thalib L. screening for diabetes in Kuwait and evaluation of risk scores. East Mediterr Health J. 2010;16(7):725–31.PubMedCrossRef
34.
go back to reference Gao WG, Dong YH, Pang ZC, Nan HR, Wang SJ, Ren J, Zhang L, Tuomilehto J, Qiao Q. simple Chinese risk score for undiagnosed diabetes. Diabet Med. 2010;27(3):274–81.PubMedCrossRef Gao WG, Dong YH, Pang ZC, Nan HR, Wang SJ, Ren J, Zhang L, Tuomilehto J, Qiao Q. simple Chinese risk score for undiagnosed diabetes. Diabet Med. 2010;27(3):274–81.PubMedCrossRef
35.
go back to reference Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligros P, Katsilambros N. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab. 2011;37(2):144–51.PubMedCrossRef Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligros P, Katsilambros N. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab. 2011;37(2):144–51.PubMedCrossRef
36.
go back to reference Silvestre MP, Jiangc Y, Volkova K, Chisholma H, Wonjoo Lee W, Poppitt SD. Evaluating FINDRISC as a screening tool for type 2 diabetes among overweight adults in the PREVIEW:NZ cohort. Prim Care Diab. 2017;11(6):561–9.CrossRef Silvestre MP, Jiangc Y, Volkova K, Chisholma H, Wonjoo Lee W, Poppitt SD. Evaluating FINDRISC as a screening tool for type 2 diabetes among overweight adults in the PREVIEW:NZ cohort. Prim Care Diab. 2017;11(6):561–9.CrossRef
37.
go back to reference Vandersmissen G, Godderis L. Evaluation of the Finnish Diabetes Risk Score (FINDRISC) for diabetes screening in occupational health care. Int J Occup Med Environ Health. 2015;28(3):587–91.PubMedCrossRef Vandersmissen G, Godderis L. Evaluation of the Finnish Diabetes Risk Score (FINDRISC) for diabetes screening in occupational health care. Int J Occup Med Environ Health. 2015;28(3):587–91.PubMedCrossRef
38.
go back to reference Tankova T, Chakarova N, Atanassova I, Dakovska L. Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucose tolerance and undetected diabetes. Diabetes Res Clin Pract. 2011;92(1):46–52.PubMedCrossRef Tankova T, Chakarova N, Atanassova I, Dakovska L. Evaluation of the Finnish Diabetes Risk Score as a screening tool for impaired fasting glucose, impaired glucose tolerance and undetected diabetes. Diabetes Res Clin Pract. 2011;92(1):46–52.PubMedCrossRef
39.
go back to reference Štiglic G, Fijačko N, Stožer A, Sheikh A, Pajnkihar M. Validation of the Finnish Diabetes Risk Score (FINDRISC) questionnaire for undiagnosed type 2 diabetes screening in the Slovenian working population. Diabetes Res Clin Pract. 2016;120:194–7.PubMedCrossRef Štiglic G, Fijačko N, Stožer A, Sheikh A, Pajnkihar M. Validation of the Finnish Diabetes Risk Score (FINDRISC) questionnaire for undiagnosed type 2 diabetes screening in the Slovenian working population. Diabetes Res Clin Pract. 2016;120:194–7.PubMedCrossRef
40.
go back to reference Witte DR, Shipley MJ, Marmot MG, Brunner EJ. Performance of existing risk scores in screening for undiagnosed diabetes: an external validation study: performance of diabetes risk scores. Diabet Med. 2010;27(7):46–53.PubMedCrossRef Witte DR, Shipley MJ, Marmot MG, Brunner EJ. Performance of existing risk scores in screening for undiagnosed diabetes: an external validation study: performance of diabetes risk scores. Diabet Med. 2010;27(7):46–53.PubMedCrossRef
41.
go back to reference Rathmann W, Martin S, Haastert B, Icks A, Holle R, Löwel H, Giani G. Performance of Screening Questionnaires and Risk Scores for Undiagnosed Diabetes: The KORA Survey 2000. Arch Intern Med. 2005;165:436.PubMedCrossRef Rathmann W, Martin S, Haastert B, Icks A, Holle R, Löwel H, Giani G. Performance of Screening Questionnaires and Risk Scores for Undiagnosed Diabetes: The KORA Survey 2000. Arch Intern Med. 2005;165:436.PubMedCrossRef
42.
go back to reference Franciosi M, Berardis GD, Rossi MCE, Sacco M, Belfiglio M, Pellegrini F, Tognoni G, Valentini M, Nicolucci A. Use of the Diabetes Risk Score for Opportunistic Screening of Undiagnosed Diabetes and Impaired Glucose Tolerance: The IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care. 2005;28(5):1187–94.PubMedCrossRef Franciosi M, Berardis GD, Rossi MCE, Sacco M, Belfiglio M, Pellegrini F, Tognoni G, Valentini M, Nicolucci A. Use of the Diabetes Risk Score for Opportunistic Screening of Undiagnosed Diabetes and Impaired Glucose Tolerance: The IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care. 2005;28(5):1187–94.PubMedCrossRef
43.
go back to reference Bernabe-Ortiz A, Perel P, Miranda JJ, Smeeth L. Diagnostic accuracy of the Finnish Diabetes Risk Score (FINDRISC) for undiagnosed T2DM in Peruvian population. Prim Care Diab. 2018;12(6):517–25.CrossRef Bernabe-Ortiz A, Perel P, Miranda JJ, Smeeth L. Diagnostic accuracy of the Finnish Diabetes Risk Score (FINDRISC) for undiagnosed T2DM in Peruvian population. Prim Care Diab. 2018;12(6):517–25.CrossRef
44.
go back to reference Gomez-Arbelaez D, Alvarado-Jurado L, Ayala-Castillo M, Forero-Naranjo L, Camacho PA, Patricio L-J. Evaluation of the Finnish Diabetes Risk Score to predict type 2 diabetes mellitus in a Colombian population: A longitudinal observational study. World J Diabetes. 2015;6(17):1337–444.PubMedPubMedCentralCrossRef Gomez-Arbelaez D, Alvarado-Jurado L, Ayala-Castillo M, Forero-Naranjo L, Camacho PA, Patricio L-J. Evaluation of the Finnish Diabetes Risk Score to predict type 2 diabetes mellitus in a Colombian population: A longitudinal observational study. World J Diabetes. 2015;6(17):1337–444.PubMedPubMedCentralCrossRef
45.
go back to reference Zhang L, Zhang Z, Zhang Y, Hu G, Chen L. Evaluation of finnish diabetes risk score in screening undiagnosed diabetes and prediabetes among U.S. adults by gender and race: NHANES 1999–2010. PLoS ONE. 2014;9(5):e97865.PubMedPubMedCentralCrossRef Zhang L, Zhang Z, Zhang Y, Hu G, Chen L. Evaluation of finnish diabetes risk score in screening undiagnosed diabetes and prediabetes among U.S. adults by gender and race: NHANES 1999–2010. PLoS ONE. 2014;9(5):e97865.PubMedPubMedCentralCrossRef
46.
go back to reference Lin J-W, Chang YC, Li HY, Chien YF, Wu MY, Tsai RY, Hsieh YC, Chen YJ, Hwang JJ, Chuang LM. Cross-sectional validation of diabetes risk scores for predicting diabetes, metabolic syndrome, and chronic kidney Disease in Taiwanese. Diabetes Care. 2009;32(12):2294–6.PubMedPubMedCentralCrossRef Lin J-W, Chang YC, Li HY, Chien YF, Wu MY, Tsai RY, Hsieh YC, Chen YJ, Hwang JJ, Chuang LM. Cross-sectional validation of diabetes risk scores for predicting diabetes, metabolic syndrome, and chronic kidney Disease in Taiwanese. Diabetes Care. 2009;32(12):2294–6.PubMedPubMedCentralCrossRef
47.
go back to reference Grundy SM. Pre-Diabetes, Metabolic Syndrome, and Cardiovascular Risk. J Am Coll Cardiol. 2012;59(7):635–43.PubMedCrossRef Grundy SM. Pre-Diabetes, Metabolic Syndrome, and Cardiovascular Risk. J Am Coll Cardiol. 2012;59(7):635–43.PubMedCrossRef
48.
go back to reference Shin J, Lee JH, Lim SY, Ha HS, Kwon HS, Park YM, Lee WC, Kang MI, Yim HW, Yoon KH, Son HY. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig. 2013;4(4):334–43.PubMedPubMedCentralCrossRef Shin J, Lee JH, Lim SY, Ha HS, Kwon HS, Park YM, Lee WC, Kang MI, Yim HW, Yoon KH, Son HY. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig. 2013;4(4):334–43.PubMedPubMedCentralCrossRef
49.
go back to reference Janghorbani M, Adineh H, Amini M. Evaluation of the Finnish Diabetes Risk Score (FINDRISC) as a Screening Tool for the Metabolic Syndrome. Rev Diabet Stud. 2013;10(4):283–92.PubMedCrossRef Janghorbani M, Adineh H, Amini M. Evaluation of the Finnish Diabetes Risk Score (FINDRISC) as a Screening Tool for the Metabolic Syndrome. Rev Diabet Stud. 2013;10(4):283–92.PubMedCrossRef
50.
go back to reference Zhang M, Zhang H, Wang C, Ren Y, Wang B, Zhang L, Yang X, Zhao Y, Han C, Pang C, Yin L, Xue Y, Zhao J, Hu D. Development and validation of a risk-score model for type 2 diabetes: a cohort study of a rural adult chinese population. PLoS ONE. 2016;11(4):e0152054.PubMedPubMedCentralCrossRef Zhang M, Zhang H, Wang C, Ren Y, Wang B, Zhang L, Yang X, Zhao Y, Han C, Pang C, Yin L, Xue Y, Zhao J, Hu D. Development and validation of a risk-score model for type 2 diabetes: a cohort study of a rural adult chinese population. PLoS ONE. 2016;11(4):e0152054.PubMedPubMedCentralCrossRef
51.
go back to reference Janghorbani M, Adineh H, Amini M. Finnish Diabetes Risk Score to predict type 2 diabetes in the Isfahan diabetes prevention study. Diabetes Res Clin Pract. 2013;102(3):202–9.PubMedCrossRef Janghorbani M, Adineh H, Amini M. Finnish Diabetes Risk Score to predict type 2 diabetes in the Isfahan diabetes prevention study. Diabetes Res Clin Pract. 2013;102(3):202–9.PubMedCrossRef
52.
go back to reference Al-Shudifat A-E, et al. Diabetes risk score in a young student population in Jordan: a cross-sectional study. J Diabetes Res. 2017;2017:1–5.CrossRef Al-Shudifat A-E, et al. Diabetes risk score in a young student population in Jordan: a cross-sectional study. J Diabetes Res. 2017;2017:1–5.CrossRef
Metadata
Title
Diagnostic accuracy of the Finnish Diabetes Risk Score for the prediction of undiagnosed type 2 diabetes, prediabetes, and metabolic syndrome in the Lebanese University
Authors
Maher Abdallah
Safa Sharbaji
Marwa Sharbaji
Zeina Daher
Tarek Faour
Zeinab Mansour
Mohammad Hneino
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2020
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-020-00590-8

Other articles of this Issue 1/2020

Diabetology & Metabolic Syndrome 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.